Biochemical pharmacology of befloxatone (MD370503), a new potent reversible MAO-A inhibitor
In vitro and ex-vivo studies show that befloxatone, a new oxazolidinone derivative, is a potent, reversible, competitive and specific MAO-A inhibitor (KiA from 1.9 to 3.6 nM and KiB/KiA ratio between 100 and 400, in the Rat and in Man, depending on the tissue). Befloxatone possesses a marked activity in antidepressant-sensitive behavioral models in rats (from 0.03 to 0.15 mg/kg po) and mice (from 0.21 to 0.29 mg/kg po). At these doses, befloxatone does not induce a significant potentiation of oral tyramine. Befloxatone is devoid of sedative, anticholinergic and cardiovascular effects. Befloxatone is rapidly and extensively distributed in rat brain, the pharmacokinetics are linear in the rat and in man in a large range of doses. Befloxatone is well tolerated in healthy volunteers and is developed as an antidepressant.
KeywordsForced Swimming Test Amine Oxidase Biochemical Pharmacology Semicarbazide Sensitive Amine Oxidase Learn Helplessness Paradigm
Unable to display preview. Download preview PDF.
- Amrein R, Allen SR, Vranesic D, Stabl M (1988) Antidepressant drug threrapy: associated risks. J Neural Transm [Suppl] 26: 73–86.Google Scholar
- Ansseau M, Caillé P, Derks C, Cieren-Puiseux I, Soubrane C, Wauthy J, Ego D, Curet O, Thiola A, Rovei V, Jarreau FX (1992a) Phase I study of single ascending doses of Befloxatone, a new reversible MAO-A inhibitor antidepressant. Proceedings XVIII CINP, Nice. Clin Neuropharmacol 15: 328B.Google Scholar
- Ansseau M, Caillé P, Derks C, Cieren-Puiseux I, Soubrane C, Wauthy J, Ego D, Rovei V, Jarreau FX (1992b) Phase I study of repeated doses of Befloxatone, a new reversible MAO-A inhibitor antidepressant. Proceedings XVIII CINP, Nice. Clin Neuropharmacol 15: 328B.Google Scholar
- Bieck PR, Antonin KH (1989) Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. J Neural Transm [Suppl] 28: 21–31.Google Scholar
- Callingham BA (1992) Possible drug interactions with reversible MAO inhibitors. Proc XVIII CINP Nice 1992. Clin Neuropharmacol [Suppl 1] 15: 71–225.Google Scholar
- Curet O, Damoiseau G, Labaune JP, Rovei V, Jarreau FX (1992) Effects of befloxatone, a new potent reversible MAO-A inhibitor, on cortex and striatum monoamines in freely moving rats. 5th International Amine Oxidase Workshop, Galway (Ireland) (unpublished).Google Scholar
- Da Prada M, Zurcher G, Wutrich I, Haefely WE (1988) On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm 26: 31–56.Google Scholar
- Ferrey G, Rovei V, Strolin Benedetti M, Gomeni C, Languillat JM (1985) Antidepressant activity of toloxatone, a selective MAO-A inhibitor, in depressed patients. In: Burrows GD, Norman TR, Dennerstein L (eds) Clinical and pharmacological studies in psychiatric disorders. John Libbey, London Paris, pp 83–86.Google Scholar
- Jarrott B, Vajda FJE (1987) The current status of monoamine oxidase and its inhibitors. Med J Aus 146: 634–638.Google Scholar
- Paykel ES (1992) Role of monoamine oxidase inhibitors in the treatment of affective disorders. Proc 5th World Congress Biological Psychiatry Florence 1991. Royal Society of Medicine Services, London New York, pp 1–8.Google Scholar
- Rovei V, Ego D, Jarreau FX (1990) Assessment of the interaction between Humoryl (Toloxatone) and oral tyramine in man vol 1. XVII CINP, Kyoto, p 43.Google Scholar